PD09-08 SHOULD A MAN WITH A HISTORY OF BREAST CANCER BE SCREENED FOR PROSTATE CANCER?

Abstract Introduction Sleep disturbances are a common problem among cancer survivors. Also, cancer patients can have altered circadian rhythms and these changes can continue to affect the patient long after the conclusion of their treatment. This analysis aims to investigate how the sleep and wake times of cancer survivors differ from the rest of the population, depending on the type of cancer. Methods Data from the 2015-2016 National Health and Nutrition Examination Survey were used. Population-weighted data on N=5,581 individuals provided complete data. History of breast, prostate, and skin cancer (melanoma or other) was self-reported. Sleep duration was self-reported in half-hour increments, and typical bedtime and waketime was self-reported. Covariates included age, sex, and race/ethnicity. Weighted linear regressions with sleep duration, bedtime and waketime were examined, with each cancer type as predictor. Results Prevalence was 1.7% for prostate cancer, 1.5% for breast cancer, 2.3% for non-melanoma skin cancer, and 0.8% for melanoma. In adjusted analyses, prostate cancer was associated with an additional 26.5 minutes of average total sleep (95%CI 2.2,50.9, p=0.03), a 23.1 bedtime minutes earlier (95%CI -40.4,-5.8, p=0.009), and no difference in waketime. Breast cancer was associated with a bedtime that was 41.1 minutes later (95%CI 10.3,72.0, p=0.009) and a waketime that was 48.7 minutes later (95%CI 12.5,84.9, p=0.008), but no difference in sleep duration. No statistically significant effects were seen for either type of skin cancer, melanoma or non-melanoma. Conclusion Prostate cancer was associated with an earlier bedtime and associated increased sleep time. Breast cancer, on the other hand, was associated with a phase delay of the sleep period but no change in sleep duration. Skin cancer was not associated with differences in sleep duration or timing. These findings may have implications for not only treatment of sleep problems in different types of cancer, but also possible circadian mechanisms. Support Dr. Grandner is supported by R01MD011600

Download Full-text

A Synchronous Diagnosis of Metastatic Male Breast Cancer and Prostate Cancer

Journal of Investigative Medicine High Impact Case Reports ◽

10.1177/2324709619847230 ◽

2019 ◽

Vol 7 ◽

pp. 232470961984723

Author(s):

Leila Moosavi ◽

Phyllis Kim ◽

An Uche ◽

Everardo Cobos

Keyword(s):

Breast Cancer ◽

Prostate Cancer ◽

Male Breast Cancer ◽

Breast Cancer Diagnosis ◽

Male Breast ◽

Breast Mass ◽

Medical Attention ◽

Cancer History ◽

History Of ◽

The Right

In this article, we present a patient diagnosed synchronously with metastatic male breast cancer and prostate cancer. This is a 63-year-old male and recent immigrant from Nigeria, who sought medical attention for progressively worsening of shortness of breath and acute progression of a chronic right breast mass. An invasive breast carcinoma was diagnosed by the core biopsy of the right breast mass. Within 2 months of his breast cancer diagnosis, the patient also was diagnosed with prostate adenocarcinoma after being worked up for urinary retention. By presenting this patient with a synchronous diagnosis with metastatic male breast cancer and prostate cancer, history of chronic right breast mass, and gynecomastia, we speculate on possible cancer etiologies and risk factors.

Download Full-text

Outcome of Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKI) Who Have a History of Prior Malignancies,

Blood ◽

10.1182/blood.v118.21.3787.3787 ◽

2011 ◽

Vol 118 (21) ◽

pp. 3787-3787

Author(s):

Paul B Koller ◽

Hagop M Kantarjian ◽

Charles Koller ◽

Elias Jabbour ◽

Susan O'Brien ◽

...

Keyword(s):

Breast Cancer ◽

Prostate Cancer ◽

Patient Outcome ◽

Median Time ◽

Cancer Diagnosis ◽

Research Funding ◽

B Cell Lymphoma ◽

Excellent Outcome ◽

History Of ◽

Prior Malignancy

Abstract Abstract 3787 Background: The natural history of CML has been irrevocably changed since the advent of TKIs with pts living longer than they ever have. Some patients have a history of previous cancers by the time they are diagnosed with CML. These pts' long-term prognosis has never been previously described. Aims: To determine the effect of prior malignancy on patient outcome after diagnosis of CML. Methods: The primary objective was to determine outcome of pts with a previous diagnosis of malignancy (PM) vs a group without (nPM). Patients included in clinical trials of TKI as initial therapy for CML in chronic phase from July 2000 to January 2011 were reviewed. Results: Of the 471 CML pts treated with frontline TKIs 47 (10%) had a PM before their CML diagnosis and 5 (1%) pts PM status could not be obtained. The median age of the patients with a PM was 60 (30–84) compared to 46 (15–86) for those with no PM. There were no significant differences in clinical characteristics between PM and nPM patients. The median from diagnosis of a PM and a diagnosis of CML was 69 months (mo) (7 mo to 707 mo). The five most common PMs were: non-melanoma skin cancer in 14 (30%), breast cancer in 10 (21%), melanoma in 5 (11%), colorectal cancer in 5 (11%), and prostate cancer in 5 (11%). “Six pts (13%) had more than one PM and 2 of those 6 had 3 PM before the diagnosis of CML, the other 4 pts had 2 PM. The PMs were treated prior to the diagnosis of CML in the following ways: 17 (36%) pts received chemotherapy for their PM, 17 (36%) received radiotherapy, and 43 (91%) received surgery. At the time of CML diagnosis 3 (6%) pts had active cancer, while the remainder of the pts with a PM were thought to be in remission. Two (4%) pts were on active therapy for their prior cancer diagnosis at the time they started on CML therapy (Tamoxifen for breast cancer in both). After the diagnosis of CML, 6 (13%) pts had a recurrence of their PM including 2 pts with basal cell cancer, and 1 each with melanoma, breast cancer, prostate cancer, and lymphoma. These recurrent malignancies were treated as follows: 3 with radiation, 2 had surgery, and 2 with chemotherapy. Five of these 6 pts continued TKI while receiving therapy for PM. The median time between diagnosis of CML and relapse of PM was 18 months. Median remission of the PM was 151 months. Also, 6 (13%) pts had a new malignancy after CML diagnosis: 2 pts with squamous skin carcinoma, and 1 each with chronic lymphocytic leukemia, papillary thyroid carcinoma, mucoepidermoid carcinoma, and large B-cell lymphoma. Treatments for the new onset malignancy after the diagnosis of CML include: surgery (4), chemotherapy (2), radiation (1), and observation (1). The median time between diagnosis of CML and a new malignancy was 39 months. Six of the 47 pts are deceased: 2 died of their PM, 2 died secondary to treatment complications for their PM, 2 died of cardiovascular issues unrelated to a cancer diagnosis. None died of CML. Initial treatment for CML was imatinib 400mg in 4/47 (9%) PM and 69/419 (16%) nPM, imatinib 800mg in 15/47 (33%) PM and 189/419 (45%) nPM, dasatinib in 11/47 (24%) PM and 78/419 (19%) nPM, and nilotinib in 16/47 (35%) PM, and 83/419(20%) nPM. The outcome of pts with PM and nPM is presented in Table 1. There was no significant different in patient outcome between pts with PM and nPM. Conclusion: Pts with CML who have prior malignancies have the same excellent outcome as patients with no prior malignancies. In the few instances in which concomitant therapy for other malignancies was required during therapy with TKI this could be accomplished with no significant toxicity. Thus, the history of prior malignancy in a patient who develops CML should not affect the decision to treat with TKI. Disclosures: Cortes: Pfizer Inc: Consultancy, Research Funding; BMS: Consultancy, Research Funding; Novartis: Consultancy, Research Funding.

Download Full-text

DNA repair germline pathogenic mutation associations with treatment duration and family history in prostate cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2019.37.7_suppl.245 ◽

2019 ◽

Vol 37 (7_suppl) ◽

pp. 245-245

Author(s):

James Vu ◽

Marcus Marie Moses ◽

Lahiru Ranasinghe ◽

Patrick Cotogno ◽

Charlotte Manogue ◽

...

Keyword(s):

Breast Cancer ◽

Prostate Cancer ◽

Dna Repair ◽

Family History ◽

Treatment Outcomes ◽

Treatment Duration ◽

Pathogenic Mutation ◽

Germline Mutations ◽

Cancer Type ◽

History Of

245 Background: Germline mutation testing for metastatic prostate cancer patients creates a potential opportunity to personalize targeted therapies to improve treatment outcomes. The goal of this study was to characterize cancer family history, and evaluate treatment outcomes, in mCRPC patients with DNA repair pathogenic germline alterations. Methods: A retrospective study of metastatic PCa patients at Tulane Cancer Center identified 246 patients undergoing germline testing using panels (30-80 genes) (Color.com or Inviate.com). Clinical annotations included family history, life-extending treatments, and treatment duration. Statistical analyses including chi-square and Wilcoxon Rank Sum. Results: In the 246 patients tested for germline mutations, 27 patients (11.0%) had ≥1 DNA repair germline pathogenic mutation (BRCA2 = 11, BRCA1 = 3, CHEK2 = 5, ATM = 3, NBN = 1, PMS2 = 2, MSH2 = 1, PALB2 = 1) while 219 patients (89.0%) possessed no pathogenic mutation in these genes. Patients with a DNA repair pathogenic mutation were more likely to have > 2 family members affected by cancer, regardless of cancer type or degree of relationship (p = 0.04). In the DNA repair population, 5 pathogenic patients had no family history of cancer (18.5%, n = 5). Patients were more likely to have a germline alteration if they had 1 or more first degree relatives affected with breast cancer (p = 0.00001). Median lines of life-extending treatments to date between the pathogenic and non-pathogenic population were equal at 2. There were no significant differences in treatment duration for abiraterone (p = 0.49), enzalutamide (p = 0.99), docetaxel (p = 0.28), cabazitaxel (p = 0.53), carboplatin+docetaxel (p = 0.41), or radium-223 (p = 0.59) between the two groups. Conclusions: In this study, DNA repair pathogenic germline mutations did not affect treatment durations or lines of therapy but these studies are underpowered. The relationship between a family history of breast cancer and a DNA repair pathogenic mutation has not previously been reported.

Download Full-text

Metachronous or synchronous male breast and prostate cancers a duality to lookout for.

F1000Research ◽

10.12688/f1000research.16997.1 ◽

2018 ◽

Vol 7 ◽

pp. 1825

Author(s):

Alain Mwamba Mukendi ◽

Eunice Van Den Berg ◽

Sugeshnee Pather ◽

Rushen Siva Padayachee

Keyword(s):

Breast Cancer ◽

Prostate Cancer ◽

Prostate Biopsy ◽

Bone Scan ◽

Digital Rectal Examination ◽

Radical Mastectomy ◽

Modified Radical Mastectomy ◽

Breast Lump ◽

History Of ◽

Prostate Cancers

Introduction: Breast cancer is well known as the stereotypical women's cancer, and prostate cancer represents the well-known stereotypical male counterpart. While prostate cancer carries the potential to metastasize to the breast, the synchronous or metachronous co-occurrence of primary breast and primary prostate cancers is quite unusual. Prostate cancer in men of African descent may have its own behavior with regards to its relationship with male breast cancer. Case presentation: Case 1: A 64 year old male presented to Chris Hani Baragwanath Hospital (CHBAH) with a 2 years history of a painless left breast lump. A core biopsy was confirmed breast carcinoma. Tamoxifen was started but, due to disease progression, he underwent left modified radical mastectomy followed by chemotherapy. Prostate biopsy was done for raised Prostate Specific Antigen (PSA) and suspicious prostate on digital rectal examination. A prostatic adenocarcinoma was subsequently diagnosed with bone metastasis on bone scan. He was started on Androgen deprivation therapy and followed up every 3 months. Case 2: A 68 year old male presented to CHBAH with a 1 year history of a painless right breast lump. A core biopsy confirmed breast cancer. Tamoxifen was started, followed by right modified radical mastectomy and chemotherapy for disease progression. A raised PSA and suspicious prostate on digital rectal examination prompted a prostate biopsy revealing a prostatic adenocarcinoma. Bone scan was negative for metastasis. He is currently on 3 monthly Androgen deprivation therapy and awaiting radiation. Conclusion: This clinical practice article not only presents this exceptionally rare duality but highlights that both cancers can coexist either as sporadic conditions, or as a result of genetic mutations. Thus, we suggest that men with prostate cancer be screened clinically, biochemically and genetically for breast cancer and vice versa.

Download Full-text

Breast cancer in a BRCA2 mutation carrier with a history of prostate cancer

Nature Reviews Clinical Oncology ◽

10.1038/nrclinonc.2009.116 ◽

2009 ◽

Vol 6 (10) ◽

pp. 604-607 ◽

Cited By ~ 2

Author(s):

Seema Panchal ◽

Orli Shachar ◽

Frances O'Malley ◽

Pavel Crystal ◽

Jaime Escallon ◽

...

Keyword(s):

Breast Cancer ◽

Prostate Cancer ◽

Mutation Carrier ◽

Brca2 Mutation ◽

Brca2 Mutation Carrier ◽

History Of

Download Full-text

Family history of breast cancer increases the risk of prostate cancer: results from the EPICAP study

Oncotarget ◽

10.18632/oncotarget.25320 ◽

2018 ◽

Vol 9 (34) ◽

pp. 23661-23669 ◽

Cited By ~ 3

Author(s):

Pierre-Jean Lamy ◽

Brigitte Trétarre ◽

Xavier Rebillard ◽

Marie Sanchez ◽

Sylvie Cénée ◽

...

Keyword(s):

Breast Cancer ◽

Prostate Cancer ◽

Family History ◽

History Of

Download Full-text

A novel germline BRCA2 mutation in a Chinese patient with prostate cancer sensitive to platinum chemotherapy: a case report

BMC Urology ◽

10.1186/s12894-021-00879-4 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Lijuan Jiang ◽

Zunguang Bai ◽

Shoulun Zhu ◽

Tingting Zhao ◽

Yining Yang ◽

...

Keyword(s):

Breast Cancer ◽

Prostate Cancer ◽

Family History ◽

Brca2 Mutation ◽

Chinese Patient ◽

Genomic Landscape ◽

Docetaxel Treatment ◽

History Of ◽

Cancer Phenotype ◽

Platinum Chemotherapy

Abstract Background Germline BRCA2 mutation is associated with an aggressive prostate cancer phenotype and indicates higher risk for hereditary cancer. Recently, numerous studies have attempted to identify the genomic landscape of prostate cancer to better understand the genomic drivers of this disease and look for the molecular targets to guide treatment selection. Case presentation We report a 67-year-old patient diagnosed with prostate cancer who experienced rapid disease progression after androgen deprivation therapy and subsequent docetaxel treatment. The patient had a strong family history of malignancy as his mother was diagnosed with breast cancer and his father was died of lung cancer. Next generation sequencing demonstrated a novel pathogenic germline BRCA2 mutation (p.Gly2181Glufs*10) in the patient. His mother with breast cancer and his son were found to have the same BRCA2 mutation. The patient experienced impressive and durable responses to carboplatin treatment. Conclusions This case demonstrated that the carboplatin could have a dramatic antitumor effect on patients with prostate cancer with germline BRCA2 mutations and family history will help to ensure that patients and their families can be provided with proper genetic counseling.

Download Full-text